Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. Chief Commercial Officer Nik Grund will engage in a Fireside Chat on Monday, July 14 at 10:00 AM EDT.
Investors and interested parties can access the presentation recording through the Investors section of Akebia's website at ir.akebia.com after the conference concludes.
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica specializzata in trattamenti per le malattie renali, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale Annuale sul Rene H.C. Wainwright, giunta alla sua quarta edizione. Il Chief Commercial Officer Nik Grund prenderà parte a una Fireside Chat lunedì 14 luglio alle 10:00 EDT.
Investitori e interessati potranno accedere alla registrazione della presentazione nella sezione Investors del sito web di Akebia all'indirizzo ir.akebia.com dopo la conclusione della conferenza.
Akebia Therapeutics (Nasdaq: AKBA), una compañía biofarmacéutica enfocada en tratamientos para enfermedades renales, ha anunciado su participación en la próxima Conferencia Virtual Anual sobre Riñón H.C. Wainwright, en su cuarta edición. El Director Comercial Nik Grund participará en una charla informal el lunes 14 de julio a las 10:00 AM EDT.
Los inversores y partes interesadas podrán acceder a la grabación de la presentación a través de la sección de inversores del sitio web de Akebia en ir.akebia.com una vez finalizada la conferencia.
Akebia Therapeutics (나스닥: AKBA)는 신장 질환 치료에 중점을 둔 바이오제약 회사로, 다가오는 H.C. Wainwright 제4회 연례 신장 가상 컨퍼런스에 참가할 것임을 발표했습니다. 최고 상업 책임자 Nik Grund는 7월 14일 월요일 오전 10시(EDT)에 Fireside Chat에 참여할 예정입니다.
투자자 및 관심 있는 분들은 컨퍼런스 종료 후 Akebia 웹사이트의 투자자 섹션 ir.akebia.com에서 발표 녹화 영상을 확인할 수 있습니다.
Akebia Therapeutics (Nasdaq : AKBA), une société biopharmaceutique spécialisée dans les traitements des maladies rénales, a annoncé sa participation à la 4e conférence virtuelle annuelle sur les reins organisée par H.C. Wainwright. Le directeur commercial Nik Grund participera à une discussion informelle le lundi 14 juillet à 10h00 EDT.
Les investisseurs et parties intéressées pourront accéder à l'enregistrement de la présentation via la section investisseurs du site web d'Akebia à l'adresse ir.akebia.com après la fin de la conférence.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Nierenerkrankungen spezialisiert, hat seine Teilnahme an der bevorstehenden 4. jährlichen virtuellen Nierenkonferenz von H.C. Wainwright angekündigt. Chief Commercial Officer Nik Grund wird am Montag, den 14. Juli um 10:00 Uhr EDT an einem Fireside Chat teilnehmen.
Investoren und Interessierte können die Aufzeichnung der Präsentation nach der Konferenz im Investorenbereich der Akebia-Website unter ir.akebia.com abrufen.
- None.
- None.
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When is Akebia Therapeutics (AKBA) presenting at the H.C. Wainwright Kidney Conference?
Who will represent Akebia Therapeutics (AKBA) at the H.C. Wainwright Conference?
How can investors access Akebia Therapeutics' (AKBA) conference presentation?
What is the focus of Akebia Therapeutics (AKBA) as a company?
